Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: MEDI6570, Placebo, Part B Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Anniston, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Advanced Cancer
Interventions: BMS-986249, Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 19
States / cities: Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more

Conditions: High Grade Glioma, CNS Tumor
Interventions: Entrectinib, Cyclophosphamide, Etoposide, Carboplatin, G-CSF, Pegfilgrastim, Surgery; Drug · Biological · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 3 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions: LTP, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 16 more

Conditions: Cancer
Interventions: CYC065; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hand Washing
Interventions: Organization Model, Data Feedback Model; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 1,624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastrointestinal Stromal Tumors
Interventions: Questionnaires, Interview, MDASI-GIST Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-955176, Placebo (Part 1), BMS-955176, Moxifloxacin, Placebo (Part 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alcohol Drinking, Heavy Drinking, Binge Drinking
Interventions: 30-Day Alcohol Abstinence Challenge; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 120 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Child Behavior, Parenting
Interventions: Standard Parent-Child Interaction Therapy (PCIT), Natural Helpers (NH); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Years to 12 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Tumor, Solid
Interventions: BDB001 (EIK1001), Atezolizumab; Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more

Conditions: Telangiectasia, Hereditary Hemorrhagic
Interventions: Pazopanib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more

Conditions: Kidney Disease, Chronic, End Stage Renal Disease, Kidney Replacement
Interventions: EPPComm Provider Training; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Livingston, New Jersey • Philadelphia, Pennsylvania

Conditions: Breast Cancer, Physical Activity
Interventions: Aerobic Training - Fixed Schedule, Resistance Training - Fixed Schedule, Walking program, Aerobic Training - Flexible Schedule, Resistance Training - Flexible Schedule, Successful Survivorship Health Education and Support Group, Flexible support groups; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Advanced Liver Cancer
Interventions: ABSK-011; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 3 more

Conditions: SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions: BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Long Beach, California • San Diego, California • Milford, Connecticut + 10 more

Conditions: Pulmonary Embolism, Pulmonary Embolism Subacute Massive
Interventions: inhaled nitric oxide (iNO); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myelogenous Leukemia
Interventions: AZD4877; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas • San Antonio, Texas

Conditions: HIV, Care-seeking, HIV Infections
Interventions: Case Management, Snowball sampling, Referral Lists; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 14 Years to 24 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Chicago, Illinois + 2 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: monalizumab; Drug
Lead sponsor: Innate Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Ozanimod placebo, Interferon beta-1a, Interferon beta-1a placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Patients With Post Orthotopic Heart Transplantation Status
Interventions: [18F](+/-)NOS; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Increasing Evidence-based Clinical Practices in VA

Symptom Inventory for Gastrointestinal Stromal Tumors

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Reset Challenge: Reducing High-risk Drinking for Cancer Prevention

Natural Helpers and PCIT

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

Development and Test of a Communication Skills Training for Transplant Providers - Aims 2 & 3

Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Effect of iNO in Patients With Submassive and Massive PE

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Linkage to Care - Part II

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.